MedTrace Logo

Lorazepam and the Risk of Serious Adverse Events

NCT07179978 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 12308

Last updated 2025-09-24

No results posted yet for this study

Summary

This is a population-based cohort study assessing whether initiating a new outpatient prescription of a higher dose of lorazepam (\>1-4 mg/day) compared to a lower dose (0.5-1 mg/day) in older adults with low kidney function (an eGFR \<45 mL/min per 1.73 m2 but not receiving dialysis or having a history of kidney transplantation) is associated with an increased 30-day risk of a composite outcome, including all-cause hospitalization, all-cause emergency visit, or all-cause mortality.

Conditions

  • Chronic Kidney Disease (CKD)

Interventions

DRUG

Lorazepam

The primary exposure of interest will be oral lorazepam at a dose range of \>1-4 mg/day.

Sponsors & Collaborators

  • London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

    lead OTHER

Eligibility

Min Age
66 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-01
Primary Completion
2024-09-01
Completion
2024-10-01

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07179978 on ClinicalTrials.gov